BCR-ABL as a target for novel therapeutic interventions

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.6, Iss.1, 2002-02, pp. : 85-101

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tyrosine Kinases as Therapeutic Targets in BCR-ABL Negative Chronic Myeloproliferative Disorders

Current Drug Targets, Vol. 8, Iss. 2, 2007-02 ,pp. : 205-216

Bentham Science Publishers

Access to resources Recommend Favorite

Allosteric Inhibitors of Bcr-Abl: Towards Novel Myristate-Pocket Binders

Current Pharmaceutical Biotechnology, Vol. 14, Iss. 5, 2013-06 ,pp. : 477-487

Bentham Science Publishers

Access to resources Recommend Favorite

C-Abl Inhibition; A Novel Therapeutic Target for Parkinson's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 17, Iss. 1, 2018-04 ,pp. : 14-21

Bentham Science Publishers

Access to resources Recommend Favorite

Structural biology in the battle against BCR-Abl

By Nagar Bhushan

Expert Opinion on Therapeutic Patents, Vol. 18, Iss. 9, 2008-09 ,pp. : 975-988

Informa Healthcare

Access to resources Recommend Favorite

Effects of BCR-ABL Inhibitors on Anti-Tumor Immunity

Current Medicinal Chemistry, Vol. 18, Iss. 34, 2011-12 ,pp. : 5174-5184

Bentham Science Publishers

Access to resources Recommend Favorite